Clinical Trial Update: Anlotinib, Penpulimab and Capecitabine in Recurrent/Metastatic Nasopharyngeal Carcinoma [Phase 2]

View source ↗

Summary

Phase 2 clinical trial evaluating a combination of Anlotinib, Penpulimab, and Capecitabine in recurrent/metastatic nasopharyngeal carcinoma. The study is curren…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Nasopharyngeal Carcinoma

Drugs mentioned

• Anlotinib (anlotinib)
• Capecitabine (capecitabine)
• Penpulimab

Snippet

Sponsor: Sun Yat-sen University | Conditions: Nasopharyngeal Neoplasms | Phase 2 | Status: ACTIVE_NOT_RECRUITING